Something quietly important happened in Washington this summer. The Health Resources and Services Administration — a federal agency most people outside healthcare have never heard of — opened a public comment window asking a very practical question: if the FDA approves psychedelic therapies, how do we actually deliver them safely, especially to people in rural counties and underserved communities?

Fifty-nine responses came back. Some were a paragraph long. Others ran twenty pages. Together they form the clearest picture yet of how the psychedelics field — drug developers, clinic operators, training schools, advocacy groups, state regulators — thinks the coming rollout should be structured. If you're someone who might one day sit in a clinical psilocybin or MDMA session (or hopes a family member could), this is the boring paperwork that will shape whether that's realistic or not.

Let's unpack what the debate is really about, and why it matters even to those of us more familiar with ayahuasca ceremonies in the jungle than with insurance-coded clinical care.

What HRSA Actually Asked

HRSA sits inside the Department of Health and Human Services, and its whole job is expanding healthcare access for people who tend to get left out — folks living in remote areas, low-income patients, and the uninsured. So when it starts thinking about psychedelic-assisted therapy, it's not asking the same questions a Silicon Valley clinic chain would ask. It's asking: can this reach a farming town in eastern Kentucky? Can a community mental health center in the Mississippi Delta actually run this?

The July request for information focused on three areas: how to train the workforce, how to deliver treatment in federally qualified health centers and rural clinics, and how technology (yes, including AI) might make the model scalable. The comment window closed in mid-August, and now the agency has a pile of stakeholder feedback to digest.

Here's why that matters. Whatever framework HRSA and its sister agencies land on will shape who can legally offer psychedelic care in the U.S., how much it costs, who gets insurance to cover it, and — bluntly — whether it becomes a genuine treatment option or another expensive wellness product for people who could already afford a retreat abroad.

The Training Question: Who Should Sit With You?

The single biggest fight buried in these comments is about credentials. Who is qualified to sit across from a patient having a psilocybin experience? The proposals range wildly.

On one end, you have professional associations arguing that only licensed clinicians — psychiatrists, psychologists, licensed clinical social workers — should be in the room during dosing. Their reasoning is straightforward: psychedelic sessions can surface trauma, trigger dissociation, and occasionally require medical judgment. If something goes sideways, you want someone who can bill Medicare and hold malpractice insurance.

On the other end are people who've been doing this work for decades — often outside formal medicine — arguing that clinical credentials alone don't make someone a good ceremony holder. What matters, they say, is whether you've been through your own deep work, whether you can sit steady when a patient starts weeping or laughing or shaking, and whether you understand set and setting as something more than a slide in a PowerPoint deck. Several submissions pointed to state-regulated frameworks in Oregon and Colorado, where facilitators go through hundreds of practicum hours without necessarily holding a clinical license.

Then there's a middle camp: a tiered model where a licensed clinician oversees care but a trained facilitator — possibly a peer specialist, possibly someone from a lineage-based training program — actually holds the room during dosing. This is closer to how the MDMA-PTSD trials were structured, and it's probably where things end up, though the devil lives in the details.

• The credential purists — safer on paper, but training bottlenecks could delay access for years.
• The experience-first camp — closer to how the medicine has actually been practiced, but harder for insurance to grasp.
• The tiered model — practical, scalable, but risks turning skilled facilitators into low-paid assistants under a medical hierarchy.

None of these are obviously right. What's clear from reading the submissions is that the field itself hasn't decided.

Can Rural Clinics Actually Do This?

The second big question HRSA asked was whether psychedelic therapy can be delivered in federally qualified health centers, certified community behavioral health clinics, and rural health clinics — the places that actually serve poor and rural Americans.

This is where the reality check hits. A typical psilocybin session runs six to eight hours. Add preparation and integration and you're looking at roughly twelve to fifteen hours of one-on-one clinical time per patient, sometimes more. A rural clinic that's already stretched thin — one psychiatrist covering three counties, no dedicated therapy rooms, staff turnover in the double digits — cannot simply add this to the schedule.

Several commenters proposed hub-and-spoke models: a regional center handles dosing days, while local clinics manage screening and integration. Others pushed for group protocols, where three or four patients dose together with a facilitator team, cutting per-patient costs significantly. Group work has real precedent — most traditional plant medicine has always been communal — but running it clinically requires careful screening for the kind of dynamics that could go wrong when several nervous systems are all wide open in the same room.

Cost came up constantly. Even the most optimistic projections put a course of clinical psilocybin therapy in the range of what many people would pay for a used car. Without Medicare and Medicaid coverage, this becomes another treatment available only to people with money — which is exactly the outcome HRSA is trying to prevent.

The AI and Telehealth Wild Card

The third topic in the RFI — technology-enabled scalability — is where things get interesting and slightly alarming. Some respondents proposed AI-driven screening tools to determine patient eligibility, remote monitoring during dosing, and app-based integration support in the weeks after a session.

There's a case for this. A well-designed screener could help catch contraindications a rushed clinician might miss. Integration coaching between sessions is often the weakest link in the whole model, and thoughtful digital tools might genuinely help. Telehealth preparation sessions could dramatically expand geographic access.

And there's a case against it. Sitting with someone during a psychedelic experience is not a task that scales through a screen. The relational safety that makes these medicines work — the felt sense that someone in the room actually sees you and isn't going anywhere — cannot be delivered by a chatbot. Several submissions pushed back hard against any suggestion that AI could substitute for a human presence during dosing, even in the name of access. They're right about that.

Why This Matters to People Considering a Retreat

You might be reading this thinking: I was researching an ayahuasca retreat in Peru, why do I care about American clinical regulations? A few reasons.

First, whatever framework emerges in the U.S. will shape global conversations about safety, ethics, and best practices. Retreat centers abroad watch these debates carefully, and the better ones already incorporate elements like structured screening, medical intake, and formal integration into their programs.

Second, if clinical psychedelic therapy does become available and affordable in the U.S. over the next few years, it changes the calculus for anyone weighing whether to travel for plant medicine. Some people genuinely need the ceremonial container and the plant lineage. Others just need effective treatment for depression or PTSD and would happily receive it closer to home. Both paths deserve to exist.

Third — and this is the honest one — the current retreat landscape is uneven. Some centers are extraordinary. Some are cash grabs with cheap facilitators and no aftercare. The credential debates HRSA is wrestling with are exactly the kind of questions you should be asking any retreat you're considering: Who's actually sitting with me? What's their training? What happens if something gets hard in the middle of the night? How much integration support do I get afterward?

What to Watch Next

HRSA will spend the coming months synthesising the responses. Expect draft guidance, more RFIs, and probably a period of pilot programs before anything gets locked in. The FDA's decisions on MDMA and psilocybin will run on their own track, but HRSA's frameworks will heavily influence how (and whether) these therapies reach communities that need them most.

A few things worth keeping an eye on:

1. Whether states like Oregon and Colorado get any acknowledgment in the federal model, or whether their facilitator training pathways get quietly ignored.
2. Whether group dosing protocols get taken seriously as a cost-lowering strategy.
3. Whether reimbursement conversations at Medicare and Medicaid start moving in parallel — because without coverage, none of the access questions matter.
4. Whether the AI and telehealth pieces get contained to preparation and integration, or whether pressure to scale pushes them further into the dosing space itself.

The people writing these twenty-page comments aren't doing it for fun. They know this is where the shape of the field is being decided. For anyone thinking about their own healing path — whether that's a clinical trial spot, a state-legal facilitator in Oregon, or an ayahuasca ceremony deep in the Amazon — it's worth understanding that the infrastructure question is finally getting asked seriously.

Retreats abroad remain, for many people, the most direct path to working with these medicines right now, and if that's the road you're considering, a curated range of ayahuasca and psilocybin retreats can be browsed on our marketplace here. Whatever route you choose, ask hard questions about training, aftercare, and who's actually going to be in the room with you. That's the real work — and no federal RFI is going to answer it for you.